

Ontario Albumin Administration Recommendations

Our Sincere Appreciation to the Working Group

ORBCoN would like to sincerely thank the contributions of our working group in the creation of this document. Your suggestions and input are greatly appreciated. A special thank you to Dr. Ian McConachie; he started the ball rolling on this project at ORBCoN's 2011 Transfusion Committee Forum with his informative starch and albumin presentation.

- Dr. Ian McConachie, Department of Anesthesia and Perioperative Medicine, Site Chief, St. Joseph's Hospital, London ON and Associate Professor Anesthesia and Perioperative Medicine, University of Western Ontario
- Dr. Lauralyn McIntyre, Department of Medicine (Critical Care), Ottawa Hospital, Ottawa Hospital Research Institute, Adjunct Scientist, Canadian Blood Services
- Dr. Deborah Cook, Professor Department of Clinical Epidemiology and Biostatistics, McMaster University, Canada Research Chair of Research Transfer in Intensive Care, Academic Chair, Critical Care Medicine, McMaster University, Director of GIM-ICU Clinical Effectiveness and Outcomes Research at St. Joseph's Hospital, Hamilton ON
- Dr. Jeannie Callum, Director Blood and Tissue Bank, Sunnybrook Health Sciences Centre, Assistant Professor Department of Medicine, University of Toronto
- Dr. Kimmo Murto, Chair Transfusion Medicine and Infusion Therapy Committee and Deputy Academic Chief, Dept. of Anesthesiology, Children's Hospital of Eastern Ontario, Assistant Professor Dept. of Anesthesiology, University of Ottawa
- Dr. Sean Dickie, Assistant Professor University of Ottawa Heart Institute, Department of Cardiac Anesthesiology
- Dr. Ramiro Arellano, Department of Anesthesiology and Perioperative Medicine, Queen's University
- Mr. Rick Trifunov, Director Plasma Products and Services, Canadian Blood Services



Acknowledgements

In addition to the working group, we were extremely fortunate to have the input and expertise of others. We sincerely appreciate the participation of the following individuals:

- Dr. Morris Blajchman, Professor Emeritus Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, Medical Director Canadian Blood Services, Hamilton Centre, Editor Transfusion Medicine Reviews
- Dr. Nadine Shehata, Assistant Professor, Division of Hematology, University of Toronto (Mount Sinai Hospital), Associate Medical Director Canadian Blood Services
- Dr. Doron Shmorgun, Assistant Professor, Division of Reproductive Medicine, Department of Obstetrics and Gynecology, University of Ottawa
- Dr. Carl Laskin, Co-Medical Director, LifeQuest Centre for Reproductive Medicine, Toronto ON

Finally, we acknowledge the funding support provided by the Ministry of Health and Long-Term Care (MOHLTC) through the Blood Programs Coordinating Office (BPCO).



Ontario Albumin Administration Recommendations

These albumin administration recommendations are offered as a possible treatment choice for some of the more common uses listed in this document. For many of these indications, albumin is not the sole treatment option. It is often used in conjunction with other substances, and in some situations, other treatment options may be considered before administering albumin. Although albumin is a relatively safe human blood product, it should be prescribed with caution. The reasons are two-fold: it is derived from human plasma and therefore carries some of the inherent risks associated with blood products and it is more costly when compared to crystalloids.

Albumin preparations are available in 5% and 25% preparations. The 5% solution has the same oncotic pressure as plasma and its uses are quite different than the hyperoncotic 25% solution. Therefore, this document is divided into 25% albumin indications and conditions treated with 5% albumin. These two solutions are very different in their scopes of use and are not interchangeable.

Note: There is a complete reference list at the end of this document. The reference content was abbreviated within the recommendation table in order to maintain a concise, user friendly format.

Disclaimer: The Ontario Albumin Administration Recommendations are not intended to replace sound clinical judgment concerning a patient's unique situation. No formal monitoring of albumin use in Ontario is being implemented at this time. Furthermore, although the advice and information contained in this document is believed to be true and accurate at the time of going to press, neither the authors nor the publishers can accept any legal responsibility for any errors or omissions that may have occurred.



25% ALBUMIN ADMINISTRATION INDICATIONS

25% Albumin			
A. Liver Disease			
Indication	Details	Suggested Dose	References/Other Information
Hepatorenal syndrome type 1 (acute onset)	Eligible for liver transplant in conjunction with vasoactive drugs. Consider terlipressin	Day 1: 1g/kg Days 2-14: 100 – 200 mL/day	<ol style="list-style-type: none"> 1. Sanyal AJ et al. Gastroent 2008;134:1360-1368. "Terlipressin is an effective treatment to improve renal function in HRS type 1" 2. Uriz J et al. J Hepatol 2000; 33:43-48. 3. Martin-Llahi M et al. Gastroent 2008;134(5):1352-1359. 4. Gluud LL et al. Cochr DB of Sys Rev 2006;4: CD005162. Cautions that although sample size is small, terlipressin may reduce mortality and improve renal function 5. Sagi SV et al. JGH 2010;25:880-885. "Terlipressin is effective in reversing HRS type 1"
Spontaneous bacterial peritonitis	All patients, in conjunction with antibiotics	Day 1: 1.5g/kg Day 3: 1g/kg	<ol style="list-style-type: none"> 6. Nazar A et al. J Hepatol 2009; 50:S86 "The administration of albumin prevents renal failure, improves survival in patients with cirrhosis and spontaneous bacterial peritonitis" 7. Sort P et al. NEJM 1999; 341(6):403-409 "In patients with cirrhosis and spontaneous bacterial peritonitis, treatment with intravenous albumin in addition to an antibiotic reduces the incidence of renal impairment and death in comparison with treatment with an antibiotic alone" 8. Sigal SH et al. Gut 2007; 56(4): 597–599 Patients with a bilirubin greater than 68.4 umol/L and/or a creatinine greater than 88.4 umol/L, albumin may be of benefit



25% ALBUMIN ADMINISTRATION INDICATIONS

25% Albumin			
A. Liver Disease (continued)			
Indication	Details	Suggested Dose	References/Other Information
Spontaneous bacterial peritonitis (continued)			9. Fernandez J et al. Hepatol 2005;42:627-634. "Albumin but not hydroxyethyl starch improves systemic hemodynamics in patients with spontaneous bacterial peritonitis"
Paracentesis	Greater than 5 L withdrawal of fluid only. Consider oral midodrine or terlipressin	6-8g/L of fluid removed	10. Lata J et al. Hepato-Gastroenterology 2007; 54:1930-1933. "...terlipressin...was as effective as IV albumin in preventing hemodynamic changes in patients with tense ascites treated by paracentesis. The treatment was well tolerated" 11. Bernardi M et al. Hepatology 2011: manuscript accepted Nov 2011, ahead of print. Reduced morbidity and mortality with albumin for paracentesis 12. Alves de Mattos A. Annals of Hepat 2011;10:S15-S20. Albumin is the treatment of choice for tense or refractory ascites when large volume paracentesis are performed 13. Singh V et al. Am J of Gastroent 2008; 103:1399-1405. Midodrine may be as effective as albumin in preventing paracentesis induced circulatory dysfunction
Post liver transplant	Abide by hepatorenal and paracentesis guidelines	See above guidelines	See above references and information



25% ALBUMIN ADMINISTRATION INDICATIONS

25% Albumin			
B. Renal Disease			
Indication	Details	Suggested Dose	References/Other Information
Hypotension during dialysis	These are some other options: saline infusions, adjust antihypertensives, caffeine midodrine, extend dialysis duration	100 mL each episode of dialysis	14. Knoll GA et al. J Am Soc Nephrol 2004; 15:487-492. Saline just as effective as albumin 15. Fortin PM et al. Cochr DB of Systematic Reviews 2010; 11:CD006758. Sparse data. Only one clinical trial
Nephrotic syndrome	NOT routinely used	NOT routinely used	No albumin treatment indications found
C. Cardiac			
Cardiopulmonary bypass	NOT routinely used	NOT routinely used	25% albumin preparations are not routinely used for bypass. See 5% albumin section
D. Maternal/Obstetrical			
Ovarian hyperstimulation syndrome (OHS)- prevention	NOT routinely used Consider cabergoline	NOT routinely used	16. Youssef MAFM et al. Cochr BD of Systematic Reviews 2011; 2:CD001302. Little evidence of albumin preventing OHS although starch products decrease the severe OHS occurrences 17. Jee BC et al. Gynecol Obstet Invest 2010;70:47-54. Albumin does not prevent OHS and may decrease pregnancy rate 18. Venetis CA et al. Fertility and Sterility 2011; 95:188-196. No OHS reduction 19. Tehraninejad ES et al. J Assist Reprod Genet 2012;29:259-264. Cabergoline is more effective than albumin



25% ALBUMIN ADMINISTRATION INDICATIONS

25% Albumin			
D. Maternal/Obstetrical (continued)			
Indication	Details	Suggested Dose	References/Other Information
Ovarian hyperstimulation syndrome- treatment	May be used. Starch products may also be considered	50 g per 1000 mL of ascites fluid removed	20. Aboulghar M et al. (Cochrane review) Human Reproduction 2002;12:3027-3032. Suggestion of prevention benefit as well 21. Lovgren TR et al. Obstet Gynecol 2009;113:493-495 22. Sansone P et al. Intensive care treatment of OHS. Ann NY Acad Sci 2011; 1221:109-118. Albumin produces a fast collection of extravascular fluid. Also indicates albumin has an important role in prevention
E. Pulmonary			
Acute Lung Injury	Use with Lasix (furosemide)	25 g over 30 mins. Repeat every 8 hours for 3 days	23. Martin G et al. Crit Care Med 2002;30:2175-2182. Improves fluid balance, oxygenation and hemodynamics 24. Martin G et al. Crit Care Med 2005;33:1681-1687. Improves oxygenation, greater net negative fluid balance and hemodynamic stability
F. Pediatric			
Chronic PICU patients with hypoalbuminemia and edema	May be considered	3-4 mL/kg, once or twice a day	No good published data, but it is common practice throughout Canada with anecdotal positive outcomes



5% ALBUMIN ADMINISTRATION INDICATIONS

5% Albumin			
F. Intensive Care Patients			
Indication	Details	Suggested Dose	References/Other Information
Burns/thermal injuries	Use only for burns with greater than 50% BSA (body surface area) when unresponsive to crystalloid. After 24 hrs: Maintain albumin conc. of 2.5 +/- 0.5g/100 mL or a total serum protein level of 5.2g/100mL	All infusion days: 0.3-0.5 mL/kg/BSA, usually 50-100 mL/hour or 1-2 mL/min	<p>25. Cooper A et al. Transfusion 2006; 46:80-89 "Treatment with 5% albumin from Day 0 to Day 14 does not decrease the burden of MODS in adult burn patients". Ringers' lactate is equally effective</p> <p>26. Fodor L et al. Int J Care Injured 2006;37:374-379. Recommends protein based colloids like albumin and plasma</p> <p>27. Faraklas I et al. J Burn Care & Research 2011;32:91-97. Albumin patients have longer hospital stays and took longer to resuscitate. However this patient group had larger and more severe injuries. Recommends further studies.</p> <p>28. Alderson P et al. Cochr DB Syst Rev 2004;4:CD001208. No evidence that albumin reduces mortality in burn patients</p>



5% ALBUMIN ADMINISTRATION INDICATIONS

5% Albumin			
F. Intensive Care Patients-continued			
Indication	Details	Suggested Dose	References/Other Information
Cardiac bypass, circuit priming	Possibly, depending on circuits used. Also institution/patient population specific NOTE: some reports indicate the use of 20-25% albumin for this purpose. However, it is diluted with non-colloid solutions to approximately 5%	Pediatric: weight dependent Adult: 1200 – 2000 mL	29. Wilkes MM et al. Ann Thorac Surg 2001;721:527-534 “Postoperative blood loss is significantly lower in cardiopulmonary bypass patients exposed to albumin than HES” 30. Riegger LQ et al. Crit Care Med 2002;30: 2649-2654. 5% albumin prime may reduce wait gain by attenuating the decrease in COP and serum albumin levels in young children after CPB. Transfusion rate may increase. Further study required. 31. Tomi T et al. Anesth Analg 2006; 102:998-1006 “The greatest impairment in hemostasis was seen after hydroxyethyl starch administration, whereas albumin appeared to have the least effect on hemostatic variables” 32. Ernest D et al. Crit Care Med 2001; 29:2299-2302 “In post-op cardiac surgical patients, infusion of 5% albumin is approx. 5X as efficient as a PV expander” but is comparable to saline with effects on changes in ISFV and oxygen delivery 33. Kuitunen A et al. Sc J of Surg 2007; 96:72-78 Albumin group of patients had better pulmonary capillary wedge pressure and hemostasis



5% ALBUMIN ADMINISTRATION INDICATIONS

5% Albumin			
F. Intensive Care Patients-continued			
Indication	Details	Suggested Dose	References/Other Information
Volume resuscitation for hypovolemia	NOT routinely used May produce harm in the critically ill	NOT routinely used	34. Delaney AP et al. Crit Care Med 2011; 39:386-391. Recommend albumin until further trials conducted although albumin patients had a lower mortality rate 35. Vincent JL et al. SOAP (Sepsis Occurrence in Acutely ill Patients) study. Crit Care 2005; 9:745-754. Indicate albumin is associated with decreased survival in acutely ill 36. Bunn F et al. Cochrane Database of Systematic Reviews 2011;3: CD001319. No colloid solution is preferable. More clinical trials required 37. Finfer S et al (SAFE study investigators). NEJM 2004;350:2247-2250. 38. Cook D. NEJM 2004;35:2294-2296.
Volume resuscitation: Brain injury	Evidence suggests patient harm-death	Evidence suggests patient harm	39. The SAFE Study Investigators. New Eng J Med 2007;357:874-884. Albumin resuscitation in traumatic brain injured patients demonstrated a high mortality rate
Mild acute lung injury and ARDS	NOT routinely used	NOT routinely used See 25% albumin	24. Martin GS et al. See 'Hypoalbuminemia'
Sepsis	Possible benefit including pediatric patients	Patient dependent	40. Finfer S et al (SAFE study investigators). Intensive Care Med 2011; 37:86-96. Albumin compared to saline did not impair renal or other organ function and may decrease risk of death 34. Delaney AP et al. See 'Volume Resuscitation'



5% ALBUMIN ADMINISTRATION INDICATIONS

5% Albumin			
G. Other Indications			
Indication	Details	Suggested Dose	References/Other Information
Plasma exchange, neurology	5% albumin ONLY	Between 1 – 1.5 plasma volume exchanges, every other day. Length of treatment patient dependent (5 – 15 exchanges)	<p>41. Llifrii S et al. Neurology 2009;73:949-953. Demonstrates clinical improvement in 63% of the patients at 6 months</p> <p>42. Balogun R et al. J of Clin Aph 2010;25:250-264. Used 5 exchanges</p> <p>43. Polenakovic M et al. Nephrol Dial Transplant 2001;16:99-100. Recommends 3 – 9 exchanges</p> <p>44. Lehmann HC et al. Arch Neurol 2006;63:930-935. Discusses 3 – 5 exchanges of a 1 to 1.5 plasma volume exchange; some patients require additional exchanges</p>



5% ALBUMIN ADMINISTRATION INDICATIONS

5% Albumin			
G. Other Indications-continued			
Indication	Details	Suggested Dose	References/Other Information
Hypoalbuminemia	NOT routinely used	NOT routinely used	<p>45. Yuan XY et al. Amer J of Surgery 2008;196:751-755. No benefits were observed when compared to the saline arm</p> <p>46. The Albumin Reviewers (Alderson P et al). Cochr DB Syst Rev 2004;4:CD001208. "There is no evidence that albumin reduces mortality in critically ill patients with burns and hypoalbuminemia"</p> <p>47. Finfer S et al (SAFE Study Investigators). BMJ 2006;333:1044. "The outcomes of resuscitation with albumin and saline are similar irrespective of patients' baseline serum albumin concentration"</p>



References for Ontario Albumin Administration Recommendations

1. Sanyal AJ et al. A Randomized, Prospective, Double-Blind, Placebo-Controlled Trail of Terlipressin for Type 1 Hepatorenal Syndrome. *Gastroent* 2008;134:1360-1368. "Terlipressin is an effective treatment to improve renal function in HRS type 1"
2. Uriz J et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. *J Hepatol* 2000; 33:43-48.
3. Martin-Llahi M et al. Terlipressin and Albumin vs Albumin in Patients with Cirrhosis and Hepatorenal Syndrome: A Randomized Study. *Gastroent* 2008; 134(5):1352-1359.
4. Gluud LL et al. Terlipressin for hepatorenal syndrome. *Cochr DB of Sys Rev* 2006;4: CD005162. Cautions that although sample size is small, terlipressin may reduce mortality and improve renal function
5. Sagi SV et al. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: A meta-analysis of randomized controlled trials. *JGH* 2010;25:880-885. "Terlipressin is effective in reversing HRS type 1"
6. Nazar A et al. Effects of albumin administration in patients with cirrhosis and bacterial infections other than spontaneous bacterial peritonitis. A randomized, controlled study. *J Hepatol* 2009; 50:S86 "The administration of albumin prevents renal failure, improves survival in patients with cirrhosis and spontaneous bacterial peritonitis"
7. Sort P et al. Effect of Intravenous Albumin on Renal Impairment and Mortality in Patients with Cirrhosis and Spontaneous Bacterial Peritonitis. *NEJM* 1999; 341(6):403-409 "In patients with cirrhosis and spontaneous bacterial peritonitis, treatment with intravenous albumin in addition to an antibiotic reduces the incidence of renal impairment and death in comparison with treatment with an antibiotic alone"
8. Sigal SH et al. Restricted use of albumin for spontaneous bacterial peritonitis. *Gut* 2007; 56(4): 597–599 Patients with a bilirubin greater than 68.4 umol/L and/or a creatinine greater than 88.4 umol/L, albumin may be of benefit



9. Fernandez J et al. A Randomized Unblinded Pilot Study Comparing Albumin versus Hydroxyethyl Starch in Spontaneous Bacterial Peritonitis. *Hepatology* 2005;42:627-634. "Albumin but not hydroxyethyl starch improves systemic hemodynamics in patients with spontaneous bacterial peritonitis"
10. Lata J et al. The efficacy of Terlipressin in Comparison with Albumin in the Prevention of Circulatory Changes after the Paracentesis of Tense Ascites : a Randomized Multicentric Study. *Hepato-Gastroenterology* 2007; 54:1930-1933. "...terlipressin...was as effective as IV albumin in preventing hemodynamic changes in patients with tense ascites treated by paracentesis. The treatment was well tolerated"
11. Bernardi M et al. Albumin infusion in patients undergoing large-volume paracentesis: A meta-analysis of randomized trials. *Hepatology* 2011:manuscript accepted Nov 2011, ahead of print. Reduced morbidity and mortality with albumin for paracentesis
12. Alves de Mattos A. Current indications for the use of albumin in the treatment of cirrhosis. *Annals of Hepat* 2011;10:S15-S20. Albumin is the treatment of choice for tense or refractory ascites when large volume paracentesis are performed
13. Singh V et al. Midodrine versus Albumin in the Prevention of Paracentesis-Induced Circulatory Dysfunction in Cirrhotics: A Randomized Pilot Study. *Am J of Gastroent* 2008; 103:1399-1405. Midodrine may be as effective as albumin in preventing paracentesis induced circulatory dysfunction
14. Knoll GA et al. A Randomized, Controlled Trial of Albumin vs Saline for the Treatment of Intradialytic Hypotension. *J Am Soc Nephrol* 2004; 15:487-492. Saline just as effective as albumin
15. Fortin PM et al. Human albumin for Intradialytic hypotension in haemodialysis patients. *Cochr DB of Systematic Reviews* 2010; 11:CD006758. Sparse data. Only one clinical trial
16. Youssef MAFM et al. Intravenous fluids for the prevention of sever ovarian hyperstimulation syndrome. *Cochr BD of Systematic Reviews* 2011; 2:CD001302. Little evidence of albumin preventing OHS although starch products decrease the severe OHS occurrences
17. Jee BC et al. Administration of IV albumin around the time of oocyte retrieval reduces pregnancy rate without preventing OHS: a systematic review and meta-analysis. *Gynecol Obstet Invest* 2010;70:47-54. Albumin does not prevent OHS and may decrease pregnancy rate



18. Venetis CA et al. Intravenous albumin administration for the prevention of severe OHS: a systematic review and metaanalysis. *Fertility and Sterility* 2011; 95:188-196. No OHS reduction
19. Tehraninejad ES et al. Comparison of cabergoline and IV albumin in the prevention of OHS: a randomized clinical trial. *J Assist Reprod Genet* 2012;29:259-264. Cabergoline is more effective than albumin
20. Aboulghar M et al. Intravenous albumin for preventing severe OHS: a Cochrane review. *Human Reproduction* 2002;12:3027-3032. Suggestion of prevention benefit as well
21. Lovgren TR et al. Spontaneous Severe OHS in Successive Pregnancies with Successful Outcomes. *Obstet Gynecol* 2009;113:493-495.
22. Sansone P et al. Intensive care treatment of OHS. *Ann NY Acad Sci* 2011; 1221:109-118. Albumin produces a fast collection of extravascular fluid. Also indicates albumin has an important role in prevention
23. Martin G et al. Albumin and furosemide therapy in hypoproteinemic patients with acute lung injury. *Crit Care Med* 2002;30:2175-2182. Improves fluid balance, oxygenation and hemodynamics
24. Martin GS et al. A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute lung injury. *CCM* 2005; 33:1681-1687. Albumin significantly improves oxygenation with greater net negative fluid balance and better maintenance of hemodynamic stability. However the authors do recommend additional randomized clinical trials
25. Cooper A et al. Five percent albumin for adult burn shock resuscitation: lack of effect on daily multiple organ dysfunction score. *Transfusion* 2006; 46:80-89. "Treatment with 5% albumin from Day 0 to Day 14 does not decrease the burden of MODS in adult burn patients". Ringers' lactate is equally effective
26. Fodor L et al. Controversies in fluid resuscitation for burn management: Literature review and our experience. *Int J Care Injured* 2006;37:374-379. Recommends protein based colloids like albumin and plasma
27. Faraklas I et al. Colloid Normalizes Resuscitation Ration in Pediatric Burns. *J Burn Care & Research* 2011;32:91-97. Albumin patients have longer hospital stays and took longer to resuscitate. However this patient group had larger and more severe injuries. Recommends further studies.
28. Alderson P et al. Human albumin solution for resuscitation and volume expansion in critically ill patients. *Cochr DB Syst Rev* 2004;4:CD001208. No evidence that albumin reduces mortality in burn patients



29. Wilkes MM et al. Albumin Versus Hydroxyethyl Starch (HES) in Cardiopulmonary Bypass Surgery: A Meta-Analysis of Postoperative Bleeding. *Ann Thorac Surg* 2001;72:527-534. "Postoperative blood loss is significantly lower in cardiopulmonary bypass patients exposed to albumin than HES"
30. Riegger LQ et al. Albumin versus crystalloid prim solution for cardiopulmonary bypass in young children. *Crit Care Med* 2002;30: 2649-2654. 5% albumin prime may reduce wait gain by attenuating the decrease in COP and serum albumin levels in young children after CPB. Transfusion rate may increase. Further study required.
31. Tomi T et al. Gelatin and Hydroxethyl Starch, but Not Albumin, Impair Hemostasis After Cardiac Surgery. *Anesth Analg* 2006; 102:998-1006 "The greatest impairment in hemostasis was seen after hydroxyethyl starch administration, whereas albumin appeared to have the least effect on hemostatic variables"
32. Ernest D et al. Distribution of normal saline and 5% albumin infusions in cardiac surgical patients. *Crit Care Med* 2001; 29:2299-2302 "In postoperative cardiac surgical patients, infusion of 5% albumin is approx. 5X as efficient as a PV expander but has comparable effects on changes in ISFV and oxygen delivery relative to normal saline"
33. Kuitunen A et al. A comparison of the hemodynamic effects of 4% succinylated gelatin, 6% hydroxyethyl starch and 4% human albumin after cardiac surgery. *Sc J of Surg* 2007; 96:72-78. Albumin group of patients had better pulmonary capillary wedge pressure and hemostasis
34. Delaney AP et al. The role of albumin as a resuscitation fluid for patients with sepsis: A systematic review and meta-analysis. *Crit Care Med* 2011; 39:386-391. Recommend albumin until further trials conducted although albumin patients had a lower mortality rate
35. Vincent JL et al. Is albumin administration in the acutely ill associated with increased mortality? Results of the SOAP (Sepsis Occurrence in Acutely ill Patients) study. *Crit Care* 2005; 9:745-754. Indicate albumin is associated with decreased survival in acutely ill
36. Bunn F, Trivedi D, Ashraf S. Colloid solutions for fluid resuscitation. *Cochrane Database of Systematic Reviews* 2011;3: CD001319. No colloid solution is preferable. More clinical trials required
37. Finfer S et al (SAFE study investigators). A comparison of albumin and saline for fluid resuscitation in the intensive care unit. *NEJM* 2004;350:2247-2250.



38. Cook D. Is albumin safe? *NEJM* 2004; 35: 2294-2296.
39. The SAFE Study Investigators. Saline or Albumin for Fluid Resuscitation in Patients with Traumatic Brain Injury. *New Eng J Med* 2007; 357: 874-884. Albumin resuscitation in traumatic brain injured patients demonstrated a high mortality rate
40. Finfer S et al (SAFE study investigators). Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis. *Intensive Care Med* 2011; 37: 86-96. Albumin compared to saline did not impair renal or other organ function and may decrease risk of death
41. Llufrü S et al. Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months. *Neurology* 2009; 73: 949-953. Plasma exchange with 5% albumin demonstrates clinical improvement in 63% of the patients at 6 months
42. Balogun R et al. Clinical Applications of Therapeutic Apheresis. *J of Clin Aph* 2010; 25: 250-264. Used 5 exchanges
43. Polenakovic M et al. *Nephrol Dial Transplant* 2001; 16: 99-100. Recommends 3-9 exchanges
44. Lehmann HC et al. Plasma exchange in neuroimmunological disorders. *Arch Neurol* 2006; 63: 930-935. Discusses 3-5 exchanges of a 1 to 1.5 plasma volume exchange; some patients require additional exchanges
45. Yuan XY et al. Is albumin administration beneficial in early stage of postoperative hypoalbuminemia following gastrointestinal surgery?: a prospective randomized controlled trial. *Amer J of Surgery* 2008; 196: 751-755. No benefits were observed when compared to the saline arm
46. The Albumin Reviewers (Alderson P et al). Human albumin solution for resuscitation and volume expansion in critically ill patients. *Cochr DB Syst Rev* 2004; 4: CD001208. "There is no evidence that albumin reduces mortality in critically ill patients with burns and hypoalbuminemia"
47. Finfer S et al (SAFE study investigators). Effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: analysis of data from the saline versus albumin fluid evaluation (SAFE) study. *BMJ* 2006; 333: 1044. "The outcomes of resuscitation with albumin and saline are similar irrespective of patients' baseline serum albumin concentration"

